3B Blackbio DX Ltd
3B Blackbio DX Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years (Page 20). Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years; export growth targeted at 20% to 25% CAGR.
From 3B Blackbio DX Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years (Page 20).
- Export business projected to grow at 20% to 25% CAGR, with potential for higher growth due to tender orders (Page 19-20).
- TRUPCR UK export revenue expected to grow by at least 30% this year, reaching INR 17-18 crores (Page 12).
- Coris acquisition sales to grow from €5.2 million, driven by AMR products and R&D pipeline, with a conservative PCR sales estimate of €0.7-1 million over 2-3 years (Page 11-15).
- Overall molecular diagnostics segment targeting combined growth of 15% to 20% (Page 9, 20).
- Capacity utilization currently at 65%; expects to accommodate up to 50% growth without significant capital expenditure (Page 16-17).
- EBITDA margins expected to stabilize around 55% due to competitive and inflationary pressures despite revenue growth (Page 16).
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Molecular diagnostics business is not capital intensive; clean rooms and equipment needed are currently utilized at about 65% capacity.
- For next 2 years, only minor capital investment expected, around INR 1 to 2 crores, mainly for facility upgrades or specific equipment for R&D.
- No plans to buy very expensive equipment like MGS technology requiring INR 7 crores investment; alternate approaches are being used.
- Coris acquisition is already integrated financially, with no major additional cash infusion needed for next 1-2 years due to adequate cash position.
- The company is open to strategic acquisitions globally but currently focusing on synergies with Coris; M&A pipeline remains active.
- Agro-chem business is static, gradual reduction in sales focus, no major capex planned there.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- There is no explicit mention of a current or expected order book or specific pending orders in the provided transcript.
- However, it is mentioned that sometimes big tender orders come unexpectedly, which cannot be projected immediately.
- The company maintains a conservative growth estimate (e.g., 20%-25% growth in exports) partly to manage the uncertainty of large orders.
- The management expresses optimism about growth driven by new product sales and expansion, implying a strong pipeline but no specific order backlog figures.
- For the Coris acquisition, no immediate cash infusion for working capital or capacity is expected as they have sufficient cash and low debt.
- The company actively pursues new acquisitions globally to synergize and grow, indicating potential future orders linked to these efforts.
How does 3B Blackbio DX Ltd rank vs peers in Healthcare Services?
Pro feature3B Blackbio DX Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio DX Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Aster DM Quality (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
- Dr Agarwal's Hea (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
- Syngene International Ltd (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
- Yatharth Hospital & Trauma Care Services Ltd (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q1 FY26 results?
Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years (Page 20). Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years; export growth targeted at 20% to 25% CAGR.
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 17.7 with a market cap of ₹1,036 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
Molecular diagnostics business is not capital intensive; clean rooms and equipment needed are currently utilized at about 65% capacity.
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.